Cingulate

Cingulate Change in Working Capital

The Change in Working Capital of Cingulate (CING) as of Nov 11, 2026 is 830,852.00 USD. In the previous year, Change in Working Capital was -4.55 M USD — a change of -118.24% (higher).

Change in Working Capital

830,852.00USD

YoY

-118.24%

Last updated:

Change in Working Capital of Cingulate is 2025 830,852.00 USD. Change in Working Capital of Cingulate was 2024 -4.55 M USD. It decreases by -118.24% higher compared to the previous year.

The Cingulate Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
1.88 M USD
Jan 1, 2020
-293,493.00 USD
Jan 1, 2021
-3.21 M USD
Jan 1, 2022
598,617.00 USD
Jan 1, 2023
7.10 M USD
Jan 1, 2024
-4.55 M USD
Jan 1, 2025
830,852.00 USD
The Cingulate Change in Working Capital history
YEARChange in Working CapitalYoY
830,852.00USD-118.24%
-4.55 MUSD-164.10%
7.10 MUSD+1,086.87%
598,617.00USD-118.63%
-3.21 MUSD+994.75%
-293,493.00USD-115.59%
1.88 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Change in Working Capital of Cingulate is 830,852.00 USD in 2025.

Change in Working Capital of Cingulate changed from -4.55 M USD to 830,852.00 USD, representing a -118.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Cingulate since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cingulate

All Key Metrics — Cingulate